Table 2.
Clinical trials regarding ICI as monotherapies in HCC treatment.
| ICIs | Patients (n) | Disease | mOS | ORR(%) | References |
|---|---|---|---|---|---|
| Nivolumab | 371 | Advanced HCC | 16.4 | 15.4 | (112) |
| Pembrolizumab | 278 | Advanced HCC | 13.9 | 18.2 | (113) |
| 104 | Advanced HCC | 12.9 | 12.9 | (114) | |
| Tislelizumab | 674 | Advanced HCC | 15.9 | 15.9 | (115) |
| Toripalimab | 36 | Advanced HCC | NR | 63.9 | (116) |
| Sintilimab | 380 | Advanced HCC | 10 | 25 | (117) |
| 36 | Advanced HCC | 15.9 | 36.1 | (118) | |
| Camrelizumab | 217 | Advanced HCC | 6 | 14.7 | (119) |
| Spartalizumab | 74 | HCC | NR | NR | (120) |
| Cemiplimab | 26 | Unresectable HCC | 3.7 | 19.2 | (121) |
| 21 | Resectable HCC | 12.4 | 15 | (122) | |
| Atezolizumab | 59 | Unresectable HCC | 6.6 | 36 | (123) |
| Atezolizumab and Bevacizumab | 336 | Advanced HCC | 12 | 67.2 | (124) |
| Durvalumab | 24 | Advanced HCC | NR | 83.3 | (125) |
| 47 | Unresectable HCC | NR | 21.3 | (126) | |
| 389 | Unresectable HCC | 16.6 | 17 | (127) | |
| Avelumab | 30 | Advanced HCC | 4.4 | 10 | (128) |
| 22 | Advanced HCC | 14.1 | 13.6 | (129) | |
| 33 | Advanced HCC | 17.2 | 55 | (130) | |
| Ipilimumab and Nivolumab | 49 | HCC | 12.8 | 31 | (131) |
| Tremelimumab | 21 | HCC | 8.2 | NR | (132) |
| 32 | HCC | 12.3 | NR | (133) | |
| 39 | HCC | 10.9 | NR | (134) | |
| Tremelimumab and Durvalumab | 40 | Unresectable HCC | NR | 15 | (135) |
| Cobalimab | 42 | HCC | NR | 46 | (136) |
ICI, Immune Checkpoint Inhibitors; n, Number; mOS, Median Overall Survival; ORR(%), Overall Response Rate; HCC, Hepatocellular Carcinoma; NR, Not reported.